U.S., Nov. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07950930) titled 'DAX-044 in Adults With Advanced Solid Tumours: a First-in-human Study of Safety, Dose and Early Anti-cancer Activity.' on Nov. 16.

Brief Summary: This is a first-in-human, multicentre, Phase 1, open-label study designed to evaluate the safety and tolerability of DAX-044 as monotherapy, and to determine its maximum tolerated dose, in adults with advanced solid tumours.

Study Start Date: Feb. 01, 2027

Study Type: INTERVENTIONAL

Condition: Advanced Solid Tumours

Intervention: DRUG: DAX-044

DAX-044 monotherapy

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Audax Biosciences Pty. Ltd.

Published by HT Digital Content Services w...